{
  "$schema": "folio-library-entry/v1",
  "id": "10665-324745",
  "blocks": [
    {
      "id": "library/10665-324745/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "Cover photograph: gloved hands hold a person's fingertip and collect a drop of blood into a thin capillary tube, next to a box of testing supplies.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "CONSIDERATIONS FOR\nDEVELOPING A \nMONITORING AND \nEVALUATION FRAMEWORK \nFOR VIRAL LOAD TESTING\nAPRIL 2019\nTECHNICAL UPDATE\nCOLLECTING AND USING DATA FOR SCALE-UP AND OUTCOMES",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover page of the April 2019 WHO technical update on developing a monitoring and evaluation framework for viral load testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "Considerations for developing a monitoring and evaluation framework for viral load testing\nWHO/CDS/HIV/19.5\n© World Health Organization 2019\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO \nlicence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the \nwork is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses \nany speci",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The copyright and cataloguing page of the 2019 WHO publication on viral load testing monitoring and evaluation, with document number, licence terms, suggested citation and disclaimers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "CONSIDERATIONS FOR\nDEVELOPING A \nMONITORING AND \nEVALUATION FRAMEWORK \nFOR VIRAL LOAD TESTING\nTECHNICAL UPDATE – APRIL 2019",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The inner title page of the April 2019 technical update on a monitoring and evaluation framework for viral load testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "CONTENTS \nAcknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n3\nAbbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n4\nExecutive summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n5\nIntroduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The table of contents, listing sections on assessing monitoring systems, indicators and service quality evaluation, and annexes with tools such as a logic model and assessment checklists.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "ACKNOWLEDGEMENTS\nWHO and the PEPFAR Viral Load Working Group prepared this publication.\nNadia Solehdin (CDC), Rituparna Pati (CDC), Laura N. Broyles (CDC), Dianna Edgil (USAID), Lara Vojnov (WHO).\nCollaborators\nWHO\nUnited States Centers for Disease Control and Prevention\nOffice of the United States Global AIDS Coordinator and Health Diplomacy\nAfrican Society for Laboratory Medicine\nUnited States Agency for International Development\nGlobal Fund to Fight AIDS, Tuberculosis and Malaria\nBill & Melinda Gates Foundation\nClinton Health Access Initiative\nElizabeth Glaser Pediatric AIDS Foundation\nWHO",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges WHO and the PEPFAR Viral Load Working Group as authors, lists collaborating organizations, and notes PEPFAR funding through the US CDC.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 6",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/page-006.md",
      "narrative": null,
      "content": "ABBREVIATIONS\nDHIS2\nDistrict Health Information System\nMER\nPEPFAR Monitoring, Evaluation and Reporting\nPEPFAR\nUnited States President’s Emergency Plan for AIDS Relief\nUNAIDS\nJoint United Nations Programme on HIV/AIDS",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A short list of abbreviations used in the publication, such as DHIS2, MER, PEPFAR and UNAIDS.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 7",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/page-007.md",
      "narrative": null,
      "content": "EXECUTIVE SUMMARY \nThe WHO consolidated guidelines on the use of \nantiretroviral drugs for treating and preventing HIV \ninfection recommend viral load as the preferred monitoring \napproach to detect and confirm the failure of antiretroviral \ntherapy. As countries invest in scaling up of routine \nviral load testing, measuring the impact of and progress \ntowards achieving the UNAIDS target that 90% of people \nreceiving antiretroviral therapy have suppressed viral loads \nby 2020 (as part of the 90–90–90 targets) is critical. This \npublication presents key considerations and examples \nof tools (pr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the publication's purpose of helping countries build national monitoring and evaluation plans as viral load testing is scaled up towards the target of 90% viral suppression. It outlines the three sections, covering assessment of data systems, indicators along the testing cascade and follow-up of people with unsuppressed viral load, and service quality assessment and evaluation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p008",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../figures/vfig-p008.webp",
      "narrative": "draft",
      "content": "Framework diagram of the health sector response to HIV, running from \"Know your epidemic\" and \"Inputs\" through \"Outputs and outcomes\" (the HIV care cascade: prevention, HIV testing service, HIV care, antiretroviral therapy, viral suppression) to \"Evaluate impact\". Below it the ten global indicators are listed, from people living with HIV and domestic funding through knowing HIV status, antiretroviral therapy and viral suppression to AIDS-related deaths and new HIV infections, with three \"90\" markers under knowing status, receiving antiretroviral therapy and viral suppression.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 8",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/page-008.md",
      "narrative": null,
      "content": "INTRODUCTION \nMonitoring the continuum of the HIV response is critical for \nensuring high quality of care and optimal clinical outcomes \nfor people living with HIV. The recent scale-up of routine \nviral load monitoring has played an integral role in tracking \nboth the individual response to antiretroviral therapy and \nperformance towards achieving programmatic goals.\nViral load testing encompasses more than conducting the \ntest within the laboratory; it requires functioning sample \nreferral networks, data systems, processes driven by \nhealth-care providers and quality control and improvement",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces viral load testing as a system that depends on sample transport, data systems and clinical follow-up as well as laboratory work, and explains the need for coordinated monitoring and evaluation plans. It notes how viral load data inform both patient care and programme performance. A figure lists global HIV cascade indicators linked to the 90-90-90 targets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 9",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/page-009.md",
      "narrative": null,
      "content": "Introduction\nprogress in achieving the ambitious UNAIDS 90–90–90 \ntargets: 90% of the people living with HIV know their HIV \nstatus, 90% of the people who know their HIV-positive \nstatus are receiving antiretroviral therapy and 90% of the \npeople receiving antiretroviral therapy have suppressed \nviral loads. Fig. 1 illustrates the HIV cascade, the key \ncascade indicators and the UNAIDS 90–90–90 targets.\nAlthough the WHO consolidated strategic information \nguidelines provide a hierarchy of indicators for a high-level \nview of the HIV response and further national indicators, \na more detailed mo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the UNAIDS 90-90-90 targets and why process, outcome and quality indicators beyond the global set are needed to track progress on viral suppression. It then sets out the publication's main objective and the topics it covers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 10",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/page-010.md",
      "narrative": null,
      "content": "1. ASSESSING AND STRENGTHENING VIRAL LOAD \nMONITORING AND EVALUATION SYSTEMS \nAssessing the current data collection, reporting and \nmanagement systems in place for implementing viral load \ntesting is one of the first steps in ensuring that countries \nhave robust systems for high-quality viral load testing \ndata. This assessment of the monitoring and evaluation \nsystems will provide a review of how systems collect \nand move data from sites and laboratories to manage \npatients and oversee programmes. Even countries that \nhave more mature viral load testing programmes can \nbenefit from comprehens",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens section 1 by stressing that assessing existing data collection and reporting systems is an early step in scaling up viral load testing. It recommends reviewing the wider HIV monitoring system where possible, mapping how data flow between facilities, transport networks and laboratories. The text refers to WHO guidance on person-centred patient monitoring for further detail.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-10",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-10.webp",
      "narrative": "draft",
      "content": "Line-drawing icon of a house with a porch and steps, used in the Fig. 2 map of the sample transport network.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-11",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-11.webp",
      "narrative": "draft",
      "content": "Illustration of a laboratory worker wearing a face mask and lab coat looking into a microscope, representing the laboratory in the Fig. 2 transport-network map.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-12",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-12.webp",
      "narrative": "draft",
      "content": "Icon of a blue post box labelled “POST”, representing the return of results by post in the Fig. 2 transport-network map.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-16",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-16.webp",
      "narrative": "draft",
      "content": "Line-drawing icon of a motor scooter, used in Fig. 2 to represent the motorbike riders who transport samples and results between health facilities and laboratory hubs.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-17",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-17.webp",
      "narrative": "draft",
      "content": "Icon of a health facility: a simple building outline with a red cross on the roof, used in the Fig. 2 transport-network map.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-21",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-21.webp",
      "narrative": "draft",
      "content": "Icon of a health facility: a simple building outline with a red cross on the roof, used in the Fig. 2 transport-network map.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p011-9",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../images/img-p011-9.webp",
      "narrative": "draft",
      "content": "Line-drawing icon of a motor scooter, used in Fig. 2 to represent the motorbike riders who transport samples and results between health facilities and laboratory hubs.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p011",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../figures/vfig-p011.webp",
      "narrative": "draft",
      "content": "Illustrated diagram of a sample transport network: samples travel by motorcycle from a cluster of health facilities to a site gathering samples and results from the catchment area (such as a lab hub), then on to a central lab. Results return along the reverse path, and can be sent to facilities by post or delivered to sites.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 11",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/page-011.md",
      "narrative": null,
      "content": "Fig. 2. Example of a map of a sample transport network and the return of results for \nviral load testing\nmolecular laboratories for viral load testing. The network \nfor transporting sample and results is an especially complex \nsystem, and monitoring and evaluation tools are generally \nrequired at every step.\nOne successful sample transport model from Uganda \ninvolves a sample transport network in which motorbike \nriders collect samples from health facilities in a designated \ncatchment area and deliver them to a laboratory hub; \nsamples are then sent from the hubs to the central \nlaboratory for",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes mapping the sample transport and results return network, using a Ugandan model of motorbike riders and laboratory hubs as an example. It suggests programmes record which monitoring tools are used at each step and adapt an example process map.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p012",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../figures/vfig-p012.webp",
      "narrative": "draft",
      "content": "Flow diagram of high-level standard operating procedures for viral load data, moving from \"Facility\" (test ordered, sample collected and dispatched) to \"Hub\", \"Central hub\" (data entry, testing, results sent), back to \"Hub\" and \"Facility\" (results received, transferred to site tools, cross-checked, reviewed), and up to \"Subnational and national\" levels (aggregation in DHIS2, review, data quality checks). Each step names the relevant monitoring and evaluation tools, such as requisition forms, specimen transport logs, laboratory information management systems and antiretroviral therapy registers.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 12",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/page-012.md",
      "narrative": null,
      "content": "Fig. 3. Example of high-level standard operating procedures for data capture, ﬂow and \nanalysis with associated monitoring and evaluation tools (in navy blue)\nUPDATING AND DEVELOPING MONITORING \nAND EVALUATION TOOLS FOR CAPTURING \nDATA RELATED TO VIRAL LOAD\nEffective tracking of viral load testing and patient \noutcomes requires multiple monitoring and evaluation tools \nand systems from multiple locations (facilities, specimen \ntransport networks and laboratories). Country programmes \nmay have existing tools that may simply require some \nupdating to effectively track viral load. It is essential",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Shows an example of standard operating procedures for capturing and analysing viral load data and lists the tools needed, such as requisition forms, sample logbooks, result forms, high viral load registers, patient records, DHIS2 and laboratory information systems. It advises reviewing how these tools collect and link data during an assessment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p013",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../figures/vfig-p013.webp",
      "narrative": "draft",
      "content": "Two boxed lists of key variables for laboratory forms. \"Specimen requisition form (entered at the clinic)\" lists items such as patient identification number, collection site, date of birth, sex, pregnancy or breastfeeding, current antiretroviral regimen, reason for the test, specimen type and adherence assessment; \"Testing requisition form (entered at the laboratory)\" lists demographic information, the viral load result and assay, specimen quality, temperature on receipt, and the dates of receipt, testing and reporting.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 13",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/page-013.md",
      "narrative": null,
      "content": "Fig. 4. Key variables to consider for laboratory requisition forms and other monitoring \nand editing tools\nforms. Some of these variables should also be integrated \ninto other monitoring and evaluation tools such as patient \ncards or charts, antiretroviral therapy registers, high \nviral load registers and viral load sample logbooks. Note \nthat all the variables (those entered at the clinic and \nat the laboratory) should be included in the laboratory \ninformation management system maintained at the \nlaboratory and also reflected in monitoring and evaluation \ntools at the site.\nCountry programme",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out key variables for viral load requisition forms and other tools, and argues that a dedicated register is needed to follow people with viral load of 1000 copies/mL or more over time. It lists the variables such a high viral load register should contain.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 14",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/page-014.md",
      "narrative": null,
      "content": "source of patient data used for reporting is accurate. \nData for sites on the numbers of individuals who received \na viral load test and their results should be compared \nbetween site-level records and systems and laboratory \nmanagement information systems to ensure that there \nare no major discrepancies. Different data sources (such \nas laboratory information management system, patient \ncharts and registers) should be cross-checked for data \nquality and consistency. This highlights the importance \nof ensuring strong links between health management \ninformation systems at facilities and labora",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses checking data quality by comparing site records with laboratory information systems and linking facility and laboratory systems. It stresses tracking outcomes for individuals rather than tests, and the need for site staff to follow procedures for moving results into patient records.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 15",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/page-015.md",
      "narrative": null,
      "content": "Table 1. Summary and suggestions to address key challenges in viral load monitoring \nand evaluation\nChallenge\nSuggestions\nUsing data from unlinked \nlaboratory, facility and/\nor national aggregate \nreporting systems\n• Map out the ﬂow of samples and results to and from facilities\n• Identify key indicators for routine monitoring that align with viral load testing guidelines, clinical \nalgorithms and standard operating procedures\n• Overlay key indicators on the ﬂow map of samples and results to and from facilities\n• Ensure that monitoring and evaluation tools with appropriate ﬁelds are available t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table of common challenges in viral load monitoring and evaluation with suggested responses, such as mapping sample flows, aligning indicators with guidelines, developing standard procedures and training, and tracking unique individuals over time.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Summary and suggestions to address key challenges in viral load monitoring and evaluation",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "Five key challenges in viral load monitoring and evaluation (unlinked reporting systems, tracking tests versus individuals, tracking patients over time, tracking coverage and suppression rates, estimating testing need), each with suggested actions to address it.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 16",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/page-016.md",
      "narrative": null,
      "content": "procedures and reflected in the quality of data. Training \nshould emphasize the following:\n• accurate and complete documentation in forms, registers \nand/or databases;\n• clarity about individual roles and responsibilities in data \ncollection and reporting;\n• review of testing algorithms, standard operating \nprocedures and processes; \n• correct methods to aggregate data for reporting;\n• consistent data capture at sites using monitoring and \nevaluation tools such as patient cards, antiretroviral \ntherapy registers and laboratory result forms;\n• clinical guidelines that inform various fields on t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists topics that data training for staff should cover and calls for ongoing data quality assessments and mentorship, especially early in tool roll-out. It also covers training on data use at patient and programme levels and ends with summary action points.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 17",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/page-017.md",
      "narrative": null,
      "content": "2. INDICATORS OF THE IMPLEMENTATION AND \nOUTCOMES OF VIRAL LOAD TESTING  \nThis publication compiles and presents several key viral \nload indicators from multiple sources, including the \nWHO consolidated strategic information guidelines for \nHIV in the health sector (1) and PEPFAR Monitoring, \nEvaluation and Reporting (MER) Guidance v2.0 (4). Country \nprogrammes can adapt relevant indicators appropriate \nto their country viral load programme monitoring and \nreporting systems and develop additional ones that reflect \ntheir priorities. Where possible, programmes should try \nto align their indicat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens section 2 on indicators for viral load testing, drawn from WHO strategic information guidelines and PEPFAR MER guidance, which countries may adapt. It stresses disaggregation by age and priority populations, introduces routine monitoring of the viral load cascade, and lists example indicators up to regimen switching.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Core indicators along the viral load testing cascade",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "Core indicators for routine monitoring at each step of the viral load testing cascade, from ordering the test and processing samples through returning results, coverage and suppression, follow-up of viral load ≥1000 copies/mL and regimen switching.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p018",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../figures/vfig-p018.webp",
      "narrative": "draft",
      "content": "Stepped cascade diagram of routine viral load testing for people living with HIV receiving antiretroviral therapy, with successively smaller bars: all receiving therapy; those requiring at least one routine annual viral load test; those with access to testing; those who received a test; those with suppressed viral loads; and, finally, those with suppressed viral loads referred to a less intensive model of care.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 18",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/page-018.md",
      "narrative": null,
      "content": "be measured. When reviewed together, the routine \nmonitoring indicators should reflect how well the country is \nimplementing viral load scale-up and progressing towards \nachieving the third 90 of the 90–90–90 targets.\nTable 2 presents a list of core indicators that are considered \nessential for routine viral load cascade monitoring and \nprogramme implementation, including monitoring patients \nwith a non-suppressed viral load. Some indicators depend \non completing multiple steps in the cascade, in which case \nthe indicator is listed with the step that is furthest along in \nthe sequence. Annex 5",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that core routine indicators show progress on viral load scale-up and the third 90 target, pointing to a fuller list in Annex 5. A table presents core indicators on processes, coverage, quality and patient outcomes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p019",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../figures/vfig-p019.webp",
      "narrative": "draft",
      "content": "Cascade diagram for people receiving antiretroviral therapy with a viral load ≥1000 copies/ml: those who received enhanced adherence counselling, then those who received a follow-up viral load test. The follow-up splits into those still ≥1000 copies/ml (in red), followed by those switched to a second-line regimen, and those with suppressed viral loads, who resume routine viral load testing (see Fig. 5).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 19",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/page-019.md",
      "narrative": null,
      "content": "receives routine viral load tests according to national \ntesting guidelines, the proportion of people receiving \nantiretroviral therapy who have access to and receive \na viral load test should be tracked to monitor viral load \ntesting coverage and outcomes. \nDeveloping cascades with associated indicators are \nimportant to monitor viral load testing coverage and the \nmaturation of systems and processes so that rates of viral \nload suppression can be interpreted accordingly.\nFig. 5 illustrates the relationship between key indicators \nalong the viral load testing cascade among people with \nsuppre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses tracking viral load testing coverage and the cascade of outcomes for people with suppressed viral load, including referral to less intensive differentiated care. It explains how to calculate denominators based on those due a test under national algorithms, with figures showing cascade indicators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p020",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../figures/vfig-p020.webp",
      "narrative": "draft",
      "content": "Bar chart example of a cascade for people with non-suppressed viral load, with six bars labelled 65 (100%), 23 (35%), 8 (12%), 15 (23%), 10 (67%) and 1 (10%). The bar category labels are not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 20",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/page-020.md",
      "narrative": null,
      "content": "MONITORING AND EVALUATION \nCONSIDERATIONS FOR PEOPLE WITHOUT \nSUPPRESSED VIRAL LOADS\nPeople without suppressed viral loads require more \nintensive monitoring and specific tools and systems to track \ninterventions. Fig. 6 illustrates the cascade for people with \nviral load ≥1000 copies/mL.\nCountry programmes should ensure that monitoring and \nevaluation tools (such as a high viral load register) are \navailable for closely tracking people without suppressed \nviral loads (≥1000 copies/mL). Data from a high viral load \nregister or logbook (Annex 3) can be used to track people \nwith a viral load re",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers monitoring of people whose viral load is 1000 copies/mL or more, using a high viral load register to track adherence counselling, repeat testing and regimen switching. A worked cascade example shows drop-off at each step.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 21",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/page-021.md",
      "narrative": null,
      "content": "With appropriate and robust monitoring and evaluation \nsystems and tools in place, data can be used to examine \nother monitoring questions related to service delivery.\n• What are the differences in rates of suppressed viral \nloads between men and women receiving antiretroviral \ntherapy?\n• Which sites have especially poor rates of suppressed \nviral loads?\n• What percentage of samples collected are rejected \nbecause of improper or insufficient collection, including \nincorrectly completed laboratory requisition forms?\n• What percentage of pregnant or breastfeeding women \nreceiving antiretroviral",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists further monitoring questions that good data can answer, such as differences in suppression by sex, site, pregnancy status and age, and sample rejection rates. It also discusses routine data quality assessment and use of results to improve data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 22",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/page-022.md",
      "narrative": null,
      "content": "ANALYSING AND USING DATA FOR \nIMPROVING PROGRAMMES\nDeveloping a clear plan for analysing and using data in \nthe early phases of scale-up can motivate staff to collect, \nreview and analyse viral load testing data. The data \nanalysis plan should include analysing overall viral load \ntesting coverage and outcomes at the site and above-\nsite levels, reviewing data by age groups and for various \npriority and key populations and analysing data from viral \nload cascades. Data analysis may also be cohort-based or \ncross-sectional, depending on the question and available \ndata. Research studies and pro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes planning for data analysis and use, including disaggregating viral load outcomes by age group and priority or key populations, given higher non-suppression among children and adolescents. It also covers presenting data for review and using them for planning, programme improvement and commodity forecasting.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 23",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/page-023.md",
      "narrative": null,
      "content": "Assessing service quality and evaluating viral load testing\n3. ASSESSING SERVICE QUALITY AND \nEVALUATING VIRAL LOAD TESTING\nCountry programmes may want to enhance the monitoring \nof viral load implementation, especially during scale-up, \nto promptly identify problems and take corrective action. \nFurther, evaluation should be planned early to ensure \nthat robust data are collected and reviewed to inform the \nimplementation and improvement of programmes.\nENHANCED MONITORING AND SERVICE \nQUALITY ASSESSMENT\nEnhanced monitoring may involve more frequent review \nof routine monitoring indicators or a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens section 3 on enhanced monitoring of viral load implementation and service quality assessment at sites against implementation standards. It also introduces planning for evaluation, including process evaluation of barriers and facilitators to testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 24",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/page-024.md",
      "narrative": null,
      "content": "technicians and monitoring and evaluation officers) and \nidentify lessons learned to inform further scale-up efforts.\nExamples of process evaluation questions\n• Was viral load testing scaled up and implemented as \nplanned? Why? What worked? What did not work?\n• How are monitoring and evaluation, programme or \nclinical and laboratory staff working together to review \nand use data on the performance of viral load testing?\n• Were staff members adequately trained to implement \nviral load testing for patient monitoring? Was there \nadequate support for viral load testing, including \nproviders at sit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Offers sample process-evaluation questions for HIV viral load testing programmes, such as whether scale-up went as planned, whether staff were trained and supported, and how well sample transport and results return work. It closes with recommendations to define the type of evaluation early and to draft evaluation protocols in time to collect baseline data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 25",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/page-025.md",
      "narrative": null,
      "content": "REFERENCES \n1. Consolidated strategic information guidelines \nfor HIV in the health sector. Geneva: World Health \nOrganization; 2015 (http://apps.who.int/iris/\nbitstream/10665/164716/1/9789241508759_eng.\npdf?ua=1&ua=1, accessed 25 March 2019).\n2. Consolidated guidelines on person-centred HIV patient \nmonitoring and case surveillance. Geneva: World Health \nOrganization; 2017 (http://www.who.int/hiv/pub/\nguidelines/person-centred-hiv-monitoring-guidelines/en, \naccessed 25 March 2019).\n3. Technical and operational considerations for \nimplementing HIV viral load testing. Geneva; World \nHealth Orga",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of references for the viral load monitoring guidance, citing mainly WHO HIV strategic information and patient monitoring guidelines, a PEPFAR indicator guide and a meta-analysis on viral suppression in children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 26",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/page-026.md",
      "narrative": null,
      "content": "ANNEX 1. LOGIC MODEL FOR ROUTINE VIRAL \nLOAD TESTING\nOUTPUTS\nACTIVITIES\nOUTPUTS\nOUTCOMES\n• Funding\n• Staff such as \nlaboratory \ntechnicians, \ntransport \nnetwork and \nclinic staff\n• Policies\n• Partnerships\n• Equipment, \nsupplies, \nreagents etc.\nLaboratory \nand specimen \ntransport \nnetwork\nPLANNING\n• Assess the capacity of staff, \nthe existing specimen transport \nnetwork, infrastructure, molecular \nlaboratories, testing modalities, IPs \nand the monitoring and evaluation  \nsystem\n• Assess the readiness of clinical \nsites and programmes\n• Select the specimen type and \nplatform or assay and the  \nt",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1 sets out a logic model for routine HIV viral load testing, running from inputs such as funding, staff, policies and equipment through planning and implementation activities to outputs and outcomes. Planning activities include assessing laboratory and transport capacity, choosing sample types and platforms, writing clinical algorithms, updating tools and training plans, and drafting a costed, phased plan, while expected long-term results include fewer AIDS-related deaths and new HIV infections.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 27",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/page-027.md",
      "narrative": null,
      "content": "ANNEX 2. TOOL AND CHECKLIST FOR ASSESSING \nMONITORING AND EVALUATION SYSTEMS FOR \nVIRAL LOAD TESTING \nPurpose: The purpose of this tool is to guide the assessment of monitoring and evaluation systems and their capacity \nto routinely monitor and track viral load testing. The process of collecting data by using monitoring and evaluation tools \nshould be well aligned with the goal of informing and improving programme implementation. This tool may be used \nthroughout the process of implementing viral load testing to inform scale-up efforts and to monitor implementation. \nIdeally, this tool would b",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Annex 2, a tool for assessing whether monitoring and evaluation systems can routinely track viral load testing, and explains that it can be used throughout implementation, ideally within a wider review of the M&E system.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 28",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/page-028.md",
      "narrative": null,
      "content": "Area of system \nto review\nAssessment questions\nFindings\nRecommendation\nData ﬂow and \ndata capture\n• Has the sample ﬂow from the site to the laboratory been clearly mapped?\n• Has the data ﬂow from the site to laboratory and back to the site (such as returning \nresults) been clearly mapped?\n• Have data capture forms been mapped to data and sample ﬂow? Is it clear what form \nwill be used at which point in sample transport and the ﬂow of data results?\n• Have data capture forms and data sources been mapped to the indicators? Is it clear \nwhere the data will come from for the various indicators? \nDa",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the M&E assessment checklist with questions on mapping sample and data flows between sites and laboratories and on whether patient cards and antiretroviral therapy registers have fields for viral load testing. It also asks whether systems can follow cohorts' viral load results over time, with space to record findings and recommendations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 29",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/page-029.md",
      "narrative": null,
      "content": "Area of system \nto review\nAssessment questions\nFindings\nRecommendation\nData reporting\n• Have  routine data reporting forms been updated to include the required ﬁelds for \nkey viral load testing indicators?\n• Have electronic reporting systems been updated to integrate the required ﬁelds for \nreporting and monitoring viral load testing and results?\n• Can the programme report on tests and/or individuals? Can the programme only \ntrack tests and not individuals? What is required to be able to track and report both \ntests and individuals?\nData analysis \nand use\n• Have monitoring and evaluation plans",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the assessment checklist with questions on data reporting, such as whether paper and electronic reporting forms include viral load indicators and can track both tests and individuals. It also covers data analysis and use, including updated M&E plans, 90–90–90 indicators, disaggregation and follow-up of data quality findings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 30",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/page-030.md",
      "narrative": null,
      "content": "Area of system \nto review\nAssessment questions\nFindings\nRecommendation\nCapacity\n• Is a plan being developed to train service providers, laboratory staff, monitoring and \nevaluation staff and others on the correct completion of tools? Does this training also \nincorporate elements of the clinical cascade to clearly show how the data relate to \nthe three 90–90–90 targets?\n• Is there a plan and schedule to provide ongoing on-site training and mentorship to \nensure compliance with national guidelines for viral load testing and documentation?\n• Is there a plan to follow up on the results of data qua",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Ends the assessment checklist with questions on capacity, including training plans for staff on completing tools, ongoing mentorship, follow-up of data quality reviews and a forum for sharing lessons on viral load monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 31",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../sections/page-031.md",
      "narrative": null,
      "content": "ANNEX 3. EXAMPLES OF KEY MONITORING AND \nEVALUATION TOOLS FOR VIRAL LOAD MONITORING \nLaboratory requisition form and viral load results form. An example from from the Government of Uganda: lab request \nform. The front side is the lab request form that accompanies the viral load sample from the facility to the laboratory hub and \nthe centralized laboratory for testing and processing. The back side is the viral load results form that reports results back to \nthe facility.\n \n \nMINISTRY OF HEALTH UGANDA \nCENTRAL PUBLIC HEALTH LABORATORIES \nP.O. Box 7272, Plot 1062-106 Butabika Road, Luzira \nToll f",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 3 begins with example M&E tools for viral load monitoring, starting with Uganda's Ministry of Health laboratory request form for HIV viral load analysis. The form captures facility, patient, treatment and sample details, with the reverse side used to send results back to the facility.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p032-128",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../images/img-p032-128.webp",
      "narrative": "draft",
      "content": "A yellow sad-face icon on the viral load results form, placed beside the result to flag an unsuppressed viral load.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/figure-img-p032-129",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../images/img-p032-129.webp",
      "narrative": "draft",
      "content": "An oval rubber stamp on the results form reading “Central Public Health Laboratories, Ministry of Health, Virology Lab”, with a small coat of arms inside.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 32",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../sections/page-032.md",
      "narrative": null,
      "content": "\"a SANAS Accredited Medical Laboratory, No. M0589\"\n1 of 1\nMINISTRY OF HEALTH UGANDA\nCENTRAL PUBLIC HEALTH LABORATORIES\nTREATMENT INFORMATION\nVIRAL LOAD RESULTS\nRECOMMENDATIONS\nFACILITY DETAILS\nName:  _______________________ \nDistrict:                O +XE\u001d\nSAMPLE DETAILS\nForm #:\n______\nSample Type:\n DBS    \n Plasma   \nPATIENT INFORMATION\nART Number:  \n_______\nOther ID:\n________\nSex:\n Female    \n Male    \n Left Blank   \nDate of Birth:\n_____________\nPhone Number:\nSAMPLE TEST INFORMATION\nSample Collection Date:  __________\nReception Date:  \n__________\nTest Date:  \n__________\nTreatment Initiation",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reproduces the results side of Uganda's central public health laboratory viral load form, with fields for sample, patient and test details and suggested clinical actions such as adherence counselling and repeat testing for unsuppressed results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 33",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../sections/page-033.md",
      "narrative": null,
      "content": "Antiretroviral therapy register with ﬁelds for recording viral load results. Example from the Government of \nUganda: an antiretroviral therapy register that can track cohorts of people receiving antiretroviral therapy. This shows an \nexample of a field to document viral load test results. In accordance with the guidelines, a viral load test result is expected \nto be documented at six months after antiretroviral therapy initiation, 12 months afterwards and then annually thereafter. \nFields in the antiretroviral therapy register for recording viral load results are essential for monitoring cohor",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Shows an example antiretroviral therapy register from Uganda that includes fields for recording viral load results so that cohorts on treatment can be tracked over time. The text notes that results are expected at six and 12 months after starting treatment and yearly afterwards, and that the register is split across two tables to fit the page. Most of the block is the register's column headings for patient details, regimens, CD4 counts and viral load by month.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 34",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/page-034.md",
      "narrative": null,
      "content": "High viral load results form. This is an optional form to record follow-up actions for people with viral load ≥1000 \ncopies/mL. This would be maintained in the patient chart or incorporated into electronic medical record systems but can \nalso be used to complete the high viral load register or logbook (see the next tool example). Key fields include: patient \ncontact information, antiretroviral therapy regimen information, data on enhanced adherence counselling session, follow-\nup viral load test date, viral load test result and whether the person switched to another antiretroviral therapy regi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents an optional form for recording follow-up of people with a viral load of 1000 copies/mL or more, covering patient and regimen details, enhanced adherence counselling sessions, repeat test results and regimen switching. Parts of the extracted form text are garbled, with missing or substituted letters.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 35",
      "pageStart": 35,
      "pageEnd": 35,
      "target": "../sections/page-035.md",
      "narrative": null,
      "content": "1st EAC session \nIdentified adherence barrier\u0006s \nAgreed -lan of action \n \n \n \n \n \n \n \n \nA\u0019\u001c\u0004inta(e demonstration by -atient\u0006careta(er done\f ☐ \u001d ☐ \u0016 \n \nCounsellor: __________________________________  Date (DD/MM/YYYY): ____/____/________ \n \n\tnd EAC session                                                                                 \nCounsellor: __________________________________  Date (DD/MM/YYYY): ____/____/________ \nAdherence since last session (e.g, over last month)    \n\u0000 Good    \n\u0000 Fair \n\u0000 Poor \nPill count done?                Y ☐ N ☐                      Pill intake: ___% \nIdentified ad",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the high viral load form with sections for the first to third enhanced adherence counselling sessions, recording adherence, pill counts, barriers and agreed action plans; some of the extracted text is garbled.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 36",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../sections/page-036.md",
      "narrative": null,
      "content": "Additional EAC session                                                                            \nCounsellor: __________________________________  Date (DD/MM/YYYY): ____/____/________ \nAdherence since last session (e.g, over last month) \n\u0000 Good    \n\u0000 Fair \n\u0000 Poor \nPill count done?                Y ☐ N ☐                      Pill intake: ___% \nIdentified adherence barrier\u0006s \nAgreed -lan of action \n \n \n \n \n \n \nAdditional EAC session                                                                            \nCounsellor: __________________________________  Date (DD/MM/YYYY): ____/____/________ \nA",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Completes the high viral load form with spaces for additional counselling sessions, the repeat viral load result and the plan for patients whose viral load stays high, with provider sign-off; parts of the extracted text are garbled.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 37",
      "pageStart": 37,
      "pageEnd": 37,
      "target": "../sections/page-037.md",
      "narrative": null,
      "content": "High viral load results follow-up register. Examples of a longitudinal register to track patients with viral load ≥1000 \ncopies/mL. Country programmes can adapt the register for their settings. Sites should complete these registers for all \npatients with an initial viral load ≥1000 copies/mL to track enhanced adherence counselling, follow-up viral load test, \nresult, outcome (such as maintained on regimen or switched) and viral load test result after outcome.\n \nThe register has been divided into two tables to fit the pages of this document. The first table corresponds to the left side \nof the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Shows an example longitudinal register for tracking patients with a viral load of 1000 copies/mL or more through enhanced adherence counselling, repeat testing and outcomes such as staying on or switching regimen. The register's column headings are listed across two tables, and programmes are invited to adapt it.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 38",
      "pageStart": 38,
      "pageEnd": 38,
      "target": "../sections/page-038.md",
      "narrative": null,
      "content": "ANNEX 4. EXAMPLE OF A TEMPLATE FOR A \nNATIONAL MONITORING AND EVALUATION PLAN \nFOR VIRAL LOAD TESTING\nThe following key sections should be included in a national monitoring and evaluation plan for viral load testing.\nProgramme monitoring\n• Main stakeholders\n• Indicators that include definitions, disaggregation, data sources and frequency of reporting\n– Baseline data and targets to be achieved with time frame\n– Responsible parties\n• Data systems and management\n• Data quality assessment\n• Data analysis\n• Data use\n• Estimated budget to conduct programme monitoring \nEvaluation\n• Purpose of the eva",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 4 gives a template for a national monitoring and evaluation plan for viral load testing, listing the key sections for programme monitoring and for evaluation. It recommends developing separate performance monitoring and evaluation plans and begins with guidance on describing stakeholders, indicators, and data systems and management.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 39",
      "pageStart": 39,
      "pageEnd": 39,
      "target": "../sections/page-039.md",
      "narrative": null,
      "content": "Data analysis and quality\nBriefly describe the data analysis and data quality assurance plans for viral load data. For example, specify how data will \nbe analysed at the site, district and national levels and by subpopulations (such as pregnant women, breastfeeding women \nand age and sex disaggregation). Data quality assurance plans can include description of checks to compare data between \nunlinked systems (such as a laboratory information system or DHIS) and/or comparing data on sites to the laboratory \ninformation system and/or DHIS.\nUsing the data and disseminating the results\nSpecify how",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the national M&E plan template with guidance on describing data analysis and quality assurance, how data will be used and shared, and the planned evaluation's purpose, questions, team, timeline and budget. It ends with sources on programme evaluation from CDC and PEPFAR.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 40",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../sections/page-040.md",
      "narrative": null,
      "content": "ANNEX 5. CORE PROGRAMME INDICATORS FOR \nSCALING UP AND IMPLEMENTING VIRAL LOAD \nTESTING\nCountry programmes should select relevant and helpful indicators for their programmes from Annex 5 (in addition to \ntheir own indicators, as applicable); programmes are not required or expected to monitor all indicators below. Further, \nprogrammes should edit or adapt indicators suggested by this framework for their settings.\nPlease note that PEPFAR monitoring, evaluation and reporting indicators are from MER 2.0, which went into effect on \n1 October 2016 and are reported annually in accordance with current",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces Annex 5, a set of core indicators for scaling up viral load testing, stressing that programmes should pick and adapt relevant indicators rather than track all of them, and noting the PEPFAR and WHO sources used.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 41",
      "pageStart": 41,
      "pageEnd": 41,
      "target": "../sections/page-041.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData \nsources and \nconsiderations\nProgramme relevance and importance \nIndicator \nguidance \nsource\nWhat is the \naccess and \ncoverage of \nviral load \nsamples \nsubmitted by \nantiretrovir al \ntherapy sites to \nthe laboratory \nor specimen?\nPercentage of \nunique viral \nload tests \nsubmitted by \nsites to the \nlaboratory \nor specimen \ntransport \nNumerator: number \nof unique viral load \ntests submitted by \nsites to the laboratory \nor specimen transport \nnetwork \nDenominator: \nnumber of people \nliving with \nHIV receiving \nantiretro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out system and process indicators for viral load testing, beginning with the share of viral load samples that antiretroviral therapy sites send to the laboratory or transport network. Each indicator gives its numerator, denominator, disaggregations, data sources and why it matters to the programme.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 42",
      "pageStart": 42,
      "pageEnd": 42,
      "target": "../sections/page-042.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData \nsources and \nconsiderations\nProgramme relevance and importance \nIndicator \nguidance \nsource\nWhat \nproportion \nof viral load \nsamples is \nrejected for \nprocessing by \neach laboratory \nor hub?\nPercentage of \nviral load tests \nrejected by \neach laboratory \nNumerator: number \nof viral load samples \nrejected at each \nlaboratory\nDenominator: \nnumber of viral load \nsamples received at \neach laboratory\nLaboratory level\n• Regional\n• Central\nSite name\nSubnational unit or \ngeographical area\nType of viral load sample:\n• Dried b",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the system and process indicators, covering items such as the proportion of samples each laboratory rejects and the reasons why. It also notes the importance of recording how long viral load instruments are out of service and why.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 43",
      "pageStart": 43,
      "pageEnd": 43,
      "target": "../sections/page-043.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData \nsources and \nconsiderations\nProgramme relevance and importance \nIndicator \nguidance \nsource\nWhat \nproportion of \nviral load test \nresults returned \nto antiretroviral \ntherapy sites \nwere recorded \nin patient \ncharts and/or \nantiretroviral \ntherapy \nregisters?\nPercentage \nof people \nliving with \nHIV receiving \nantiretroviral \ntherapy with a \nviral load result \ndocumented \nin the medical \nrecord within \nthe past \n12 months\nNumerator: number \nof adults and \nchildren receiving \nantiretroviral therapy \nwith a viral load",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the system and process indicators with measures of whether returned viral load results are recorded in patient charts and registers. It notes that gaps can be explored through data quality assessments and supportive supervision visits.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 44",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../sections/page-044.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData sources and considerations\nProgramme relevance and \nimportance \nIndicator \nguidance source\nWhat proportion \nof people \nreceiving \nantiretroviral \ntherapy received \na viral load test \nat six months \nafter initiating \nantiretroviral \ntherapy and had \nsuppressed viral \nloads?\nPercentage \nof people \nreceiving \nantiretroviral \ntherapy who \nhad viral load \nmonitored at \nsix months\n[WHO: VLS.6]\nNumerator:  number \nof people living with \nHIV and receiving \nantiretroviral therapy \nwith at least one viral \nload test result in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Starts the health outcome indicators for viral load scale-up, such as the share of people on antiretroviral therapy who had a viral load test at six months and who were virally suppressed. Each indicator lists its definition, disaggregation, data sources, relevance and the WHO or PEPFAR guidance it comes from.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 45",
      "pageStart": 45,
      "pageEnd": 45,
      "target": "../sections/page-045.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData sources and considerations\nProgramme relevance and \nimportance \nIndicator \nguidance source\nWhat is the \ncoverage of viral \nload testing?\nPercentage \nof people \nreceiving \nantiretroviral \ntherapy \nreceiving a viral \nload test in the \npast 12 months\nNumerator: number of \npeople living with HIV \nreceiving antiretroviral \ntherapy with at least \none viral load test result \nin their medical record \nin the past 12 months\nDenominator: number \nof people living \nwith HIV receiving \nantiretroviral therapy \nfor at least 12 month",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the health outcome indicators with measures of viral load testing coverage in the past 12 months and of viral suppression among people on treatment. It gives numerators, denominators, disaggregations, data sources and the PEPFAR or WHO source for each.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 46",
      "pageStart": 46,
      "pageEnd": 46,
      "target": "../sections/page-046.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData sources and considerations\nProgramme relevance and \nimportance \nIndicator \nguidance source\nWhat proportion \nof people living \nwith HIV with \nsuppressed viral \nloads (<1000 \ncopies/ml) have \nbeen referred to \na less intensive \nmodel of care \nor differentiated \nservice delivery \nin the past \n12 months?\nPercentage of \npeople living \nwith HIV with \nsuppressed \nviral loads \n(<1000 copies/\nml) who have \nbeen referred \nto a less \nintensive model \nof care or \ndifferentiated \nservice delivery \nin the past 12 \nmonths\nNumerator",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the outcome indicators with measures such as the share of virally suppressed people referred to less intensive, differentiated models of care. It also covers indicators for people with non-suppressed viral loads, noting that programmes should adapt them to their enhanced adherence counselling guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/figure-vfig-p047",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 47,
      "pageEnd": 47,
      "target": "../figures/vfig-p047.webp",
      "narrative": "draft",
      "content": "Indicator reference table (printed rotated) with columns for monitoring question, indicator, numerator and denominator, disaggregation, data sources and considerations, programme relevance and importance, and indicator guidance source. Its two rows cover the percentage of people receiving antiretroviral therapy with viral load ≥1000 copies/mL who received a follow-up viral load test within six months, and the percentage who then suppressed to <1000 copies/mL on follow-up testing.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-324745/blocks/prose-page-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 47",
      "pageStart": 47,
      "pageEnd": 47,
      "target": "../sections/page-047.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData sources and considerations\nProgramme relevance and \nimportance \nIndicator \nguidance source\nWhat proportion \nof people \nreceiving \nantiretroviral \ntherapy with \na viral load \n≥1000 copies/\nmL received a \nfollow-up viral \nload test within \nsix months?\nPercentage \nof people \nreceiving \nantiretroviral \ntherapy with \nviral load \n≥1000 copies/\nmL who \nreceived a \nfollow-up viral \nload test within \nsix months \nafter enhanced \nadherence \ncounselling \n(or according \nto national \nguidelines)\nNumerator: number of \npeople living",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the outcome indicators with the proportion of people with a viral load of 1000 copies/mL or more who had a follow-up test within six months of enhanced adherence counselling. It explains that such indicators help show the impact of interventions and inform estimates of HIV drug resistance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 48",
      "pageStart": 48,
      "pageEnd": 48,
      "target": "../sections/page-048.md",
      "narrative": null,
      "content": "Monitoring \nquestion\nIndicator\nNumerator and \ndenominator\nDisaggregation\nData sources and considerations\nProgramme relevance and \nimportance \nIndicator \nguidance source\nWhat proportion \nof people \nreceiving \nantiretroviral \ntherapy with \nrepeat viral load \n≥1000 copies/\nml switch to \nsecond- or third-\nline antiretroviral \ntherapy \nregimens?\nPercentage \nof people \nliving with \nHIV receiving \nantiretroviral \ntherapy \nwith two \ndocumented \nviral load test \nresults ≥1000 \ncopies/mL \nswitching to \nsecond- or \nthird-line \nantiretroviral \ntherapy \nregimens\nNumerator: number of \npeople living with HIV",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Ends the outcome indicators with the share of people with two consecutive high viral load results who switch to second- or third-line antiretroviral regimens. It closes with references to WHO and PEPFAR guidance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 49",
      "pageStart": 49,
      "pageEnd": 49,
      "target": "../sections/page-049.md",
      "narrative": null,
      "content": "ANNEX 6. PEPFAR EVALUATION STANDARDS OF \nPRACTICE \n1. Engage stakeholders\n2. Clearly state evaluation questions, purpose and objectives\n3. Use appropriate evaluation design, methods and analytical techniques\n4. Address ethical considerations and assurances\n5. Identify resources and articulate a budget\n6. Construct data collection and management plans\n7. Ensure appropriate evaluator qualifications and evaluation independence\n8. Monitor the planning and implementation of an evaluation\n9. Produce high-quality evaluation reports\n10. Disseminate the results\n11. Use the findings to improve programme",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 6 lists the eleven PEPFAR evaluation standards of practice, from engaging stakeholders and stating clear questions to producing quality reports and using findings to improve programmes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 50",
      "pageStart": 50,
      "pageEnd": 50,
      "target": "../sections/page-050.md",
      "narrative": null,
      "content": "ANNEX 7. DIFFERENCES BETWEEN TYPES OF \nEVALUATION AND OPERATIONS RESEARCHa\nType\nDescription\nExamples of questions\nUse of results\nProcess \nevaluation\nDetermines whether the programme is \nreaching the right target populations, \nhow a programme is being implemented \nand what factors help or hinder \nprogramme implementation to inform \nprogramme planning and development \nand take corrective action\n• Were target populations reached? \nWhy not?\n• Was the programme implemented as \nplanned? Why? What worked? What \ndid not work?\n• What were the kinds of problems \nencountered in delivering the \nprogramme",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 7 compares types of evaluation and operations research in a table describing each type, sample questions and how results are used. It begins with process evaluation, which looks at whether a programme reaches its target populations and is carried out as planned, and ends with sources including a CDC presentation on economic evaluation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 51",
      "pageStart": 51,
      "pageEnd": 51,
      "target": "../sections/page-051.md",
      "narrative": null,
      "content": "Type\nDescription\nExamples of questions\nUse of results\nOperations \nresearch\nOperations research aims to develop \nsolutions to current operational \nproblems of speciﬁc health programmes \nor speciﬁc service delivery components \nof the health system, such as a health \ndistrict or a hospital. This research is \ncharacterized by a strong problem-\nsolving focus and an urgency to ﬁnd \nsolutions. Its demand-driven nature \nand close association with health-\ncare delivery and routine health-care \noperations ensure the operational \nrelevance of the research activities and \nrapid uptake and local use of res",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Concludes the comparison table with operations research, described as problem-focused, demand-driven research to solve practical issues in health programmes and service delivery, with example questions and sources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 52",
      "pageStart": 52,
      "pageEnd": 52,
      "target": "../sections/page-052.md",
      "narrative": null,
      "content": "Notes\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank page for notes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-053",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 53",
      "pageStart": 53,
      "pageEnd": 53,
      "target": "../sections/page-053.md",
      "narrative": null,
      "content": "Notes\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank page for notes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-054",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 54",
      "pageStart": 54,
      "pageEnd": 54,
      "target": "../sections/page-054.md",
      "narrative": null,
      "content": "Notes\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank notes page made up of the heading \"Notes\" and dotted lines for writing; the large word count reflects the dot leaders, not content.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-055",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 55",
      "pageStart": 55,
      "pageEnd": 55,
      "target": "../sections/page-055.md",
      "narrative": null,
      "content": "_(no text on this page)_",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A blank page with no extractable text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-324745/blocks/prose-page-056",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 56",
      "pageStart": 56,
      "pageEnd": 56,
      "target": "../sections/page-056.md",
      "narrative": null,
      "content": "For more information, contact:\nWorld Health Organization \nDepartment of HIV/AIDS \n20, avenue Appia \n1211 Geneva 27 \nSwitzerland\nE-mail: hiv-aids@who.int\nwww.who.int/hiv",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The back-cover contact block giving the address, e-mail and website of the WHO Department of HIV/AIDS in Geneva.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
